Medigene AG confirmed its financial forecast for 2022 published in the Group Management's Discussion and Analysis 2021 and continues to expect revenues of EUR 23 million - EUR 28 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.135 EUR | 0.00% |
|
-6.38% | -27.87% |
06-27 | Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness | CI |
05-21 | Medigene, BioNTech Extend Cancer Immunotherapy Partnership | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.87% | 35.85M | |
+15.20% | 121B | |
+19.67% | 113B | |
+16.97% | 26.02B | |
-23.86% | 19.39B | |
-19.65% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- MDG1 Stock
- News Medigene AG
- Medigene AG Confirms Revenue Forecast for 2022